Navigation Links
Zafgen Secures $45 Million in Series E Financing
Date:12/4/2013

CAMBRIDGE, Mass., Dec. 4, 2013 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has secured $45 million in a Series E equity financing.  New investors include RA Capital Management, Brookside Capital, Venrock, Alta Partners, an undisclosed blue chip investor, and a private investor.  Proceeds from the financing will be used to support the continued development of beloranib, the Company's obesity therapeutic.  Zafgen recently reported Phase 2 study results, which demonstrated that beloranib treatment led to significant weight loss and improvements in multiple cardiometabolic risk factors in 147 obese subjects.

"We are excited to add this group of new investors to our syndicate and to obtain continued investment from Alta Partners who led our Series D round last year, as we continue to advance our clinical testing for beloranib in severe obesity and related orphan indications," said Thomas Hughes, Ph.D., president and chief executive officer, Zafgen, Inc.  "With their support, we look forward to building on our recent Phase 2 results and expanding the beloranib program to help patients who suffer from these serious diseases."  

"Zafgen has continued to attract high quality investors to its syndicate in support of beloranib," said Peter Barrett of Atlas Venture and Chairman of the Board of Zafgen.  "Zafgen's newest investors support some of the most innovative companies and their investment demonstrates confidence in beloranib as a unique pharmacotherapeutic with the potential to address the unmet needs of severely obese patients."

About Zafgen, Inc.

Zafgen is an innovative company dedicated to addressing the unmet need of severely obese patients and related orphan indications by bringing beloranib, a first-in-class no
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
4. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
5. Calithera Biosciences Secures $35 Million in Series D Financing
6. Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
7. Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation
8. Predilytics Secures Additional Funding and Expands Board of Directors
9. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
10. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
11. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... CHESTERBROOK, Pa. , July 31, 2014   ... a fully integrated specialty biopharmaceutical company, today announced that ... of 2014 on Thursday, August 7, 2014 before the ... will conduct a conference call that day at 8:30 ... second quarter of 2014. The presentation slides to be ...
(Date:7/31/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... of its lead molecule, Anatabine Citrate, in ... Clinical, The Translational Pharmaceutics Company, based in the ... early development programs. The Company expects to ... of the third quarter with the Medicines Healthcare products ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group ... market intelligence product Marketrack to now include ChinaTrack; the ... device landscape in an interactive dashboard providing detailed brand-level ... volumes at a hospital level. Other key ... Updated data feed: In addition to end-user surveys of ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... , HOPKINTON, Mass., Nov. 2 Caliper Life Sciences, Inc. ... tools, presented at a training session for reviewers from the ... of the LabChip GX platform for high throughput screening and ... accept the FDA,s invitation to present our LabChip platform to ...
... This week begins American Diabetes Month® - a ... the launch of a new campaign by the American Diabetes ... and one of its National Strategic Partners, Liberty Medical Supply, ... give diabetes patients practical tips and advice for living with ...
Cached Medicine Technology:Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2Educational Video Series Released for American Diabetes Month 2Educational Video Series Released for American Diabetes Month 3Educational Video Series Released for American Diabetes Month 4
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) issued ... strokes, heart attacks, and other injuries in men who ... as the transferee judge and ordered what could be ... , As one of his first organizing acts, Judge ... who will move the litigation forward on behalf of ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... are obese and work in manufacturing jobs may have significantly less ... In a study of 32 people -- half were obese, half ... endurance times that were about 60 percent longer. Obesity also ... performance. Being older -- 50 to 65 years ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 As it ... behalf of women who allegedly experienced the spread of ... in gynecological surgeries, Bernstein Liebhard LLP notes the growing ... number of power morcellators marketed by its Ethicon, Inc. ... The New York Times, some critics of the company ...
(Date:8/1/2014)... and the benefits of a cancer diagnosis may improve ... a study conducted by a researcher at the University ... an expressive writing intervention is the writing instruction. Otherwise, ... events. Writing a journal can be therapeutic, but oftentimes ... it,s effective or not," said Qian Lu, assistant professor ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
Breaking Medicine News(10 mins):Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
... obstructive sleep apnea (OSA), a sleep disorder associated with ... coronary arteries, according to a study presented today at ... America (RSNA). "Our study reveals that individuals with ... form of atherosclerosis that puts them at risk for ...
... Using functional magnetic resonance imaging (fMRI), researchers have captured ... stimulus with and without acupuncture to determine acupuncture,s effect ... study, which the researchers say suggest the effectiveness of ... the Radiological Society of North America (RSNA). "Until ...
... Whitehead Institute researchers have shown in mouse models that ... leukemia and accelerate the disease,s progression. Their results are ... of the National Academy of Sciences (PNAS). "MicroRNAs ... mice, can upregulation of a microRNA actually cause the ...
... bottle of pomegranate juice at the store because you,ve learned ... replete with antioxidants that bring health benefits. But wait: ... is the product label you have carefully read promising more ... California, Riverside is determined to find out. Cynthia ...
... MONDAY, Nov. 29 (HealthDay News) -- Women have worse ... (PAD) in their lower extremities, a new study has ... for PAD surgery in lower extremities conducted from 1998 ... Of those hospitalizations, 162,730 (43.6 percent) were women. ...
... News) -- Patients who trust that their doctor would tell ... those who doubt their physician would own up to the ... doesn,t mean patients are less likely to sue. Researchers ... about 40 percent had personal experience with medical errors or ...
Cached Medicine News:Health News:People with sleep apnea at higher risk for aggressive heart disease 2Health News:Acupuncture changes brain's perception and processing of pain 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3Health News:How authentic is your pomegranate juice? 2Health News:Peripheral Arterial Surgery Outcomes Worse for Women: Study 2Health News:Trust in Doctor May Affect Reaction to Medical Error 2
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Peribulbar Needle, 25 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Scleral Blade tip 5700 style, straight. Dimensions: 15.2 mm (L) x 3.4 mm (W). Cut: 2.7 mm....
Blade tip handle....
Medicine Products: